Electrolytically severable joint for endovascular embolic devices
Abstract
This invention is an apparatus for endovascular occlusion through the formation of thrombi in arteries, veins, aneurysms, vascular malformations, and arteriovenous fistulas. In particular, it deals with a sacrificial link between an endovascular device which is introduced to and is intended to remain at the desired thrombus formation site and the device used to introduce the device. The invention further includes a method for introduction of the device and its electrolytic separation.

Term
Term ended
Projected expiry passed 1 November 2014, 11.9 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
13 claims: 3 independent, 10 dependent
- 1A guidewire for use in the formation of a vascular occlusion, in combination with a catheter, the guidewire comprising:a core wire (102,120,126), said core wire having an axis and not being susceptible to electrolytic disintegration in blood;a discrete, sacrificial, severable link (106,122,134) susceptible to electrolytic disintegration in blood distal to and severably connected to said core wire (102,120,126);and an elongate tip portion (104) extending distally beyond said core wire (102,120,126) and adapted to form said occlusion at a selected site within a mammal vasculature, said elongate tip portion (104) being severable from the core wire (102,120,126) upon electrolytic disintegration of the sacrificial link (106,122,134) and not being susceptible to electrolytic disintegration in blood.
Independent claims3
46 paragraphs, as filed
Field of the Invention
0001This invention is an apparatus for endovascular occlusion through the formation of thrombi in arteries, veins, aneurysms, vascular malformations, and arteriovenous fistulas. In particular, it deals with a sacrificial link between an endovascular device which is introduced to and is intended to remain at the desired thrombus formation site and the device used to introduce the device. The invention further includes a method for introduction of the device and its electrolytic separation.
Background of the Invention
0002Approximately 25,000 intracranial aneurysms rupture each year in North America. The primary purpose of treatment for a ruptured intracranial aneurysm is to prevent rebleeding. There are a variety of ways to treat ruptured and non-ruptured aneurysms.
0003Possibly the most widely known of these procedures is an extravascular approach using surgery or microsurgery. This treatment is common with intracranial berry aneurysms. The method comprises a step of clipping the neck of the aneurysm, performing a suture ligation of the neck, or wrapping the entire aneurysm. Each of these procedures is formed by intrusive invasion into the body and performed from the outside of the aneurysm or target site. General anesthesia, craniotomy, brain retraction, and placement of a clip around the neck of the aneurysm are typically required in these surgical procedures. The surgical procedure is often delayed while waiting for the patient to stabilize medically. For this reason, many patients die from the underlying disease or defect prior to the initiation of the procedure.
0004Another procedure -- the extra-intravascular approach -- involves surgically exposing or stereotactically reaching an aneurysm with a probe. The wall of the aneurysm is then perforated from the outside and various techniques are used to occlude the interior in order to prevent it from rebleeding. The techniques used to occlude the aneurysm include electrothrombosis, adhesive embolization, hog hair embolization, and ferromagnetic thrombosis. These procedures are discussed in U.S. Patent No. 5,122,136 to Guglielmi et al., the entirety of which is incorporated by notice.
0005A still further approach is the least invasive and is additionally described in Guglielmi et al. It is the endovascular approach. In this approach, the interior of the aneurysm is entered by use of a catheter such as those shown in Engelson (Catheter Guidewire), U.S. Patent No. 4,884,579 and also in Engelson (Catheter for Guidewire Tracking), U.S. Patent No. 4,739,768. These patents describe devices utilizing guidewires and catheters which allow access to the aneurysm from remote portions of the body. Specifically by the use of catheters having very flexible distal regions and guidewires which are steerable to the region of the aneurysm, embolic devices which may be delivered through the catheter are an alternative to the extravascular and extra-intravascular approaches.
0006The endovascular approach typically includes two major sections. The first section involves the introduction of the catheter to the aneurysm site using devices such as shown in the Engelson patents. The second section often involves filling the aneurysm in some fashion or another. For instance, a balloon may be introduced into the aneurysm from the distal portion of the catheter where it is inflated, detached, and left to occlude the aneurysm. In this way, the parent artery is preserved. Balloons are becoming less in favor because of the difficulty in introducing the balloon into the aneurysm sac, the possibility of an aneurysm rupture due to overinflation of the balloon within the aneurysm, and the risk associated with the traction produced when detaching the balloon.
0007A highly desirable embolism-forming device which may be introduced into an aneurysm using endovascular placement procedures, is found in U.S. Patent No. 4,994,069, to Ritchart et al. There is described a device -- typically a platinum/tungsten alloy coil having a very small diameter -- which may be introduced into an aneurysm through a catheter such as those described in Engelson above. These coils are often made of wire having a diameter of 2-6 mils. The coil diameter may be 10-30 mils. These soft, flexible coils may be of any length desirable and appropriate for the site to be occluded. For instance, the coils may be used to fill a berry aneurysm. Within a short period of time after the filling of the aneurysm with the embolic device, a thrombus forms in the aneurysm and is shortly thereafter complemented with a collagenous material which significantly lessens the potential for aneurysm rupture.
0008Coils such as seen in Ritchart et al. may be delivered to the vasculature site in a variety of ways including, e.g., mechanically detaching them from the delivery device as is shown in U.S. Patent No. 5,250,071 to Palermo or by electrolytic detachment as is shown in Guglielmi et al. (U.S. Patent No. 5,122,136) as was discussed above.
0009Guglielmi et al. shows an embolism-forming device and procedure for using that device. Specifically, Guglielmi et al. fills a vascular cavity such as an aneurysm with an embolic device such as a platinum coil which coil has been endovascularly delivered. The coil is then severed from its insertion tool by the application of a small electric current. Desirably, the insertion device involves a guidewire which is attached at its distal end to an embolic device by an electrolytic, sacrificial joint. Guglielmi et al. suggests that when the embolic device is a platinum coil, the platinum coil may be 1-50 cm. or longer as is necessary. Proximal of the embolic coil is a guidewire, often stainless steel in construction. The guidewire is used to push the platinum embolic coil, obviously with great gentleness, into the vascular site to be occluded. The patent shows a variety ways of linking the embolic coil to the pusher guidewire. For instance, the guidewire is tapered at its distal end and the distal tip of the guidewire is soldered into the proximal end of the embolic coil. Additionally, a stainless steel coil is wrapped coaxially about the distal tapered portion of the guidewire to provide column strength to the guidewire. This coaxial stainless steel wire is joined both to the guidewire and to the embolic coil. Insulation may be used to cover a portion of the strength-providing stainless steel coil. This arrangement provides for two regions which must be electrolytically severed before the embolic coil is severed from the guidewire.
0010A further variation of the Guglielmi detachable coil is one in which the distal tip of the stainless steel guidewire is not soldered to the proximal end of the embolic device. A simple conical stainless steel wire is included from the stainless steel guidewire to the embolic coil.
0011A further variation found in Guglielmi et al. includes a thin, threadlike extension between the guidewire core and the proximal end of the embolic coil. In this way, the guidewire does not extend to the embolic coil, but instead relies upon a separately introduced extension.
0012A continuation-in-part application to the Guglielmi et al patent discussed above, U.S. Patent No. 5,354,295, issued on October 11, 1994, entitled "IMPROVEMENTS IN AN ENDOVASCULAR ELECTROLYTICALLY DETACHABLE WIRE AND TIP FOR THE FORMATION OF THROMBUS IN ARTERIES, VEINS, ANEURYSMS, VASCULAR MALFORMATIONS AND ARTERIOVENOUS FISTULAS" describes the use of mechanically detachable embolic devices as well as those which are electrolytically detachable. The embolic devices may be augmented with attached filaments.
0013Dr. Taki has devised a variation of the Guglielmi detachable coil using a copper link between the guidewire and the coil.
0014None of the noted procedures using electrolytically detachable embolic devices suggests the concept of limiting the size of the sacrificial link to allow more precise placement of the embolic device and facile, quick detachment.
Summary of the Invention
0015As noted above, this invention is a device for forming a vascular occlusion at a selected site. Generally, the device comprises a guidewire having a distal tip which distal tip may be introduced into the selected vascular site or cavity. The guidewire is joined to the distal tip or embolic device in such a way that the vascular device may be electrolytically detached by application of a current to the core or guidewire. The improvement involves the use of a discrete, sacrificial link between the core wire and the vascular device to allow clean and quick detachment from the guidewire. The focussed electrolysis found at the sacrificial site reduces the overall possibility of occurrence of multiple electrolysis sites and liberation of large particles from those sites.
0016There are several variations of the sacrificial joint involving extensive electrical insulation about the core wire and any supporting coil devices or the use of direct coating on electrolytically susceptible surfaces.
Brief Description of the Drawings
0017Figures 1, 2, 3, 5, and 6 show sideview, partial cross-sectional views of variations of the inventive, electrolytically susceptible, sacrificial link between a core wire and an embolic device.
0018Figure 4 shows a cross section of the variation shown in Figure 3.
0019Figure 7 shows a close up side view of a variation such as found in Figure 6.
0020Figure 8 shows side view of a typical assembly involving the inventive sacrificial link used in this invention.
0021Figures 9 and 10 schematically depict the method for deploying the vasoocclusive device using the inventive sacrificial link.
Description of the Invention
0022Each of the discrete sacrificial joints discussed below may be used in the device shown in U.S. Patent No. 5,122,136 to Guglielmi et al. the entirety of which patent is incorporated by reference.
0023The first of such variations is shown in Figure 1. The assembly <b>100</b> is made up generally of a guide or core wire <b>102</b> which tapers at its distal end to a point and is soldered into the proximal end of a vasoocclusive device <b>104</b>, which in this case is a coil. All of the core wire <b>102</b> is covered with an insulating material such as Teflon®, polyurethane, polyethylene, polypropylene, or other suitable polymeric material, except the most distal exposed joint or sacrificial link <b>106</b>. Link <b>106</b> is not coated with an electrical insulator and is of a material which is susceptible to electrolytic dissolution in blood. The core wire <b>102</b> is typically stainless steel and may be disposed within a protective catheter not shown. Stainless steel guidewire <b>102</b> typically is approximately 10-30 mils. in diameter. Often the guidewire is 50-300 cm. in length, that is to say, from the entry site outside the body to sacrificial link <b>106</b>.
0024Sacrificial link <b>106</b> is a discrete link. By "discrete" we mean to say preferably that the joint is substantially dissolved upon release of the vasoocclusive device <b>104</b>. Alternatively, "discrete" may be meant to means that the length of the link <b>108</b> is no greater than the diameter of the sacrificial link <b>106</b> or that the electrolytic surface present after the vasoocclusive device is released is not substantially greater than would be a circle having the diameter of the sacrificial link <b>106</b>.
0025Also shown in Figure 1 is a coil <b>108</b> which is soldered at its proximal end and, typically, is designed to provide some column strength to the guidewire assembly while not detrimentally affecting the flexibility of the tapered portion of the core wire <b>102</b>. Obviously, in the area where the support coil <b>108</b> is soldered to core wire <b>102</b>, the coating on <b>102</b> is not present so to allow the solder to adhere to metal surfaces. Further, on the distal tip of core wire <b>102</b> may be found a pair of insulators: sleeve <b>110</b> and end plug <b>112</b> which serve to further remove the stainless steel coil <b>108</b> from contact with the blood while the step of electrolytic detachment is carried out. Preferably, the end plug <b>112</b> and sleeve <b>110</b> are adhesively attached to each other so to form an electrically insulating or electrolysis-tight housing about coil <b>108</b>. The end plug <b>112</b> and sleeve <b>110</b> form a planar surface in the Figure which is generally planar and perpendicular to the axis of the core wire <b>102</b>.
0026As noted above, the distal end of guidewire or core wire <b>102</b> is inserted into the solder joint <b>114</b> forming the proximal end of vasoocclusive device <b>104</b>.
0027As will be discussed in more detail below, the discrete sacrificial link <b>106</b> is completely or substantially completely dissolved during electrolysis.
0028Figure 2 shows a most preferred variation of the Figure 1 device having a guide or core wire <b>102</b> which may taper at its distal end to a point and which is soldered into the proximal end of a vasoocclusive device <b>104</b>, which in this case is a coil. Similarly, the distal portion of the guidewire <b>102</b> having stainless steel coil <b>108</b> thereabout is all enclosed in an end plug <b>107</b> and sleeve <b>109</b> to provide additional protection to the guidewire and included stainless steel coil <b>108</b>. The major difference between the Figure 1 device and the link assembly shown in Figure 2 is the use of a bias formed distal region. The combination of end plug <b>107</b> and sleeve <b>109</b> allow clear access by blood (and therefore electrolytic current) to the sacrificial link (106). The end plug <b>112</b> and sleeve <b>110</b> form a planar surface in the Figure which is generally planar but not perpendicular to the axis of the core wire <b>102</b>.
0029Obviously, the shape of the surface is, in and of itself, of much criticality except to the extent it allows reasonably free access of the blood to the sacrificial joint <b>106</b>. Curved, slotted, and other variations of the end surface are also contemplated in this invention.
0030Figure 3 shows a variation of the device shown in Figures 1 or 2 in that the core wire <b>102</b> comes down to a point having a sacrificial link <b>106</b> which is soldered into solder joint <b>114</b> in vasoocclusive device <b>104</b>. The coil <b>108</b> provided to give additional column strength to the core wire <b>102</b> is also present. End plug <b>112</b> is also found in this device. The variation is in the outer sleeve <b>116</b>. In this variation, the outer sleeve extends up to and is in contact with the solder joint <b>114</b> found at the end of vasoocclusive device <b>104</b>. To allow the sacrificial link <b>106</b> to have electrical contact with the patient's blood, a sleeve <b>116</b> has a number of openings therein to allow contact of the blood with the sacrificial link <b>106</b>. The openings <b>118</b> may be seen both in Figure 3 and in a cross-section found in Figure 4. The end plug <b>112</b> and the cross-section of the sacrificial link <b>106</b> may also be seen in Figure 4. The variation shown in Figure 3 may have slightly more physical strength but because of the smaller area through openings <b>118</b>, the step of electrolysis may be slightly slower.
0031Figure 5 shows another variation of the inventive sacrificial joint. The device again has a guidewire or core wire <b>120</b> which tapers down to a small point which is soldered into solder joint <b>114</b> on the end of vasoocclusive device <b>104</b>. Again, as with the device in Figures 1, 2, and 3, all except the most distal portion <b>122</b> of core wire <b>120</b> is coated with an insulating material such as Teflon® polymer or other suitable insulating polymers. In this instance, however, the sacrificial link <b>122</b> forming the distal end of core wire <b>120</b> is surrounded, as is a portion of the taper on guidewire <b>120</b> with a release spring <b>124</b>. Release spring <b>124</b> is attached to the guidewire body <b>120</b> but is not attached to the solder joint <b>114</b> on vasoocclusive device <b>104</b>. The release spring <b>124</b> is slightly compressed. It, however, has some space between its adjacent windings as it is found in place on the core wire <b>120</b>. In this way, blood has access to sacrificial link <b>122</b> between the adjacent windings on release spring <b>124</b>. When the sacrificial link <b>122</b> is dissolved, release spring <b>124</b> gently pushes vasoocclusive device <b>104</b> away from the tip of the guidewire or core wire <b>120</b>. Release spring <b>124</b> is completely insulated except, obviously, for the portion which is connected to the core wire <b>120</b>, if welding or soldering of release spring <b>124</b> is had to core wire <b>120</b>.
0032Figure 6 shows a variation of the inventive device in which core wire <b>126</b> tapers down and is either directly soldered to the interior of coil <b>128</b> at solder joint <b>130</b> or is connected to a link which is then soldered at joint <b>130</b>. A support spring <b>132</b> interior to coil <b>128</b> may be used in the same way as was shown in Figures 1, 2, and 3. As a safety factor, coil <b>128</b> and support spring <b>132</b> are fixed to core wire <b>126</b>. The coil <b>128</b> is also electrically connected to core wire <b>126</b>. All of core wire <b>126</b>, coil <b>128</b>, and support spring <b>132</b> are insulated so as to prevent electrolysis upon application of voltage to core wire <b>126</b>. The exception to this insulation is a scribe or score mark <b>134</b> which forms the discrete sacrificial link. Score mark <b>134</b> is shown in more detail on Figure 7. Again, the effect of the scribe or score mark <b>134</b> as shown in Figure 6 is that the electrolysis takes place only at that small area and when the electrolysis has completely severed coil <b>128</b> at that point, there is little potential for electrolysis to take place at any other site on the core wire <b>126</b> or spring <b>128</b>.
0033Vasoocclusive device <b>104</b> is shown in each of the drawings above to be a coil. It may be a coil or a braid or other vasoocclusive device as is already known. The vasoocclusive device may be covered or connected with fibrous materials tied to the outside of the coil or braided onto the outer cover of the coil as desired. Such fibrous adjuvants may be found in U.S. Pat. Appl. No. 07/965,973, to Phelps <u>et al</u>, or in U.S. Pat. Appl. No. 07/771,013, entitled "Vasoocclusion Coil with Attached Fibrous Elements", the entirety of which are incorporated by reference.
0034Figure 8 shows a typical layout involving the inventive discrete sacrificial joint <b>106</b> as was generally shown in the Figures above. In Figure 8, a somewhat conventional Teflon® laminated or similarly insulated stainless steel guidewire assembly <b>140</b> may be placed within a protective catheter. As was noted above, stainless steel guidewire <b>140</b> may have a diameter of approximately 10-30 mils. In the noted embodiment in Figure 8, guidewire assembly <b>140</b> is tapered at its distal end to form a conical section <b>142</b> which joins a further section <b>144</b> which extends along a length of guidewire <b>146</b>. Section <b>144</b> then gradually narrows down to a thinner section <b>148</b>. The guidewire assembly <b>140</b>, as noted above, may be placed within a catheter body and is typically 50-200 cm. in length down to sacrificial link <b>106</b>. As was shown in Figure 1, the distal section of guidewire assembly <b>140</b> has an outer Teflon® sleeve <b>150</b> (or sleeve of other appropriate insulating material). Furthermore, it has an end plug <b>152</b> to permit isolation of the guidewire electrically from the blood except at sacrificial discrete link <b>106</b>. The proximal end of vasoocclusive device <b>104</b> is typically a soldered tip or a joint <b>114</b>. Preferably, vasoocclusive device <b>104</b>, when a coil, forms a secondary loop after it emanates from the end of the catheter. The distal end of vasoocclusive device <b>104</b> may also have an end plug or tip to prevent Punctures of the aneurysm when introduced into the aneurysm sac.
0035As noted, the coil or vasoocclusive device <b>104</b> may be pre-biased to form a cylinder or conical envelope. However, the vasoocclusive device <b>104</b> is extremely soft and its overall shape is easily deformed. When inserted within the catheter (not shown), the vasoocclusive device <b>104</b> is easily straightened so to lie axially within the catheter. Once ejected from the tip of the catheter, vasoocclusive device <b>104</b> may form a shape shown in Figure 8 or may be loosely deformed to conform to the interior shape of the aneurysm.
0036Figure 9 shows the placement of the inventive devices shown above within a vessel <b>156</b> with the tip of catheter <b>158</b> placed near neck <b>160</b> of aneurysm <b>162</b>. Vasoocclusive device <b>164</b> is fed into aneurysm <b>162</b> at least until sacrificial link <b>106</b> is exposed beyond the distal tip of the catheter <b>158</b>. A positive electric current of approximately 0.01-2 milli-amps at 0.1-6 volts is applied to guidewire <b>166</b> to form a thrombus within aneurysm <b>162</b>. The negative pole <b>168</b> of power supply <b>170</b> is typically placed in electrical contact with the skin.
0037After the thrombus has been formed and the aneurysm occluded, vasoocclusive device <b>164</b> is detached from guidewire <b>166</b> by electrolytic disintegration of sacrificial link <b>106</b>.
0038After sacrificial link <b>106</b> is completely dissolved by electrolytic action, typically within 3-10 minutes, the guidewire <b>166</b>, catheter <b>156</b>, are removed vessel <b>156</b>, leaving aneurysm <b>162</b> occluded as shown in Figure 10.
0039The process is typically practiced under fluoroscopic control with local anesthesia. A transfemoral catheter is utilized to treat a cerebral aneurysm and is usually introduced at the groin. When the vasoocclusive device <b>164</b> is platinum, it is not effected by electrolysis. When the guidewire and pertinent portions of the supporting coils at the distal tip of the guidewire are adequately coated with insulating coverings, only the exposed portion at the sacrificial link <b>106</b> is effected by the electrolysis.
0040Many alterations and modifications may be made by those having ordinary skill in the art without departing from the spirit and scope of the invention. Therefore, it must be understood that the shape of the tip or distal platinum coil used in combination with the guidewire according to the invention may be provided with a variety of shapes and envelopes.
0041The illustrated embodiments have been used only for the purposes of clarity and should not be taken as limiting the invention as defined by the following claims.
5 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US9814466B2 | Cited by | United States of America | Applicant |
| US10342683B2 | Cited by | United States of America | Applicant |
| US10413310B2 | Cited by | United States of America | Applicant |
| US11839380B2 | Cited by | United States of America | Applicant |
| US9808256B2 | Cited by | United States of America | Applicant |
| US9717503B2 | Cited by | United States of America | Applicant |
| US11426293B2 | Cited by | United States of America | Applicant |
| US10426644B2 | Cited by | United States of America | Applicant |
| US11304712B2 | Cited by | United States of America | Applicant |
| US10722255B2 | Cited by | United States of America | Applicant |
| US10076399B2 | Cited by | United States of America | Applicant |
| US10456151B2 | Cited by | United States of America | Applicant |
| US10874401B2 | Cited by | United States of America | Applicant |
| US4884579A | Cites | United States of America | Search report |
| US4994069A | Cites | United States of America | Search report |
| US5108407A | Cites | United States of America | Search report |
| US5122136A | Cites | United States of America | Search report |
| WO9316650A1 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| WO9410936A1 | Cites | World Intellectual Property Organization (WIPO) | Search report |
48 members in 14 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 147529 | United States of America | – | |
| 14752993 | United States of America | A | |
| 95900494 | European Patent Office (EPO) | A |
Members48
| Document | Office | Kind | |
|---|---|---|---|
| IL111485D0 | Israel | D0 | |
| CA2151924A1 | Canada | A1 | |
| WO9512367A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU8130394A | Australia | A | |
| US5423829A | United States of America | A | |
| JPH08501015A | Japan | A | |
| TW273505B | Taiwan Province of China | B | |
| NO961682D0 | Norway | D0 | |
| NO961756D0 | Norway | D0 | |
| NO961756L | Norway | L | |
| EP0726745A4 | European Patent Office (EPO) | A4 | |
| EP0726745A1 | European Patent Office (EPO) | A1 | |
| CA2175102A1 | Canada | A1 | |
| NO961682L | Norway | L | |
| EP0739606A1 | European Patent Office (EPO) | A1 | |
| AU5193496A | Australia | A | |
| KR960705511A | Republic of Korea | A | |
| JPH08299457A | Japan | A | |
| KR960037068A | Republic of Korea | A | |
| AU675892B2 | Australia | B2 | |
| US5624449A | United States of America | A | |
| JP2610412B2 | Japan | B2 | |
| EP0807410A2This record | European Patent Office (EPO) | A2 | |
| EP0726745B1 | European Patent Office (EPO) | B1 | |
| AT162384T | Austria | T | |
| ATE162384T1 | Austria | T1 | |
| DE69408155D1 | Germany | D1 | |
| EP0807410A3 | European Patent Office (EPO) | A3 | |
| DK0726745T3 | Denmark | T3 | |
| ES2113173T3 | Spain | T3 | |
| DE69408155T2 | Germany | T2 | |
| AU696160B2 | Australia | B2 | |
| CA2151924C | Canada | C | |
| CA2175102C | Canada | C | |
| JP2001178830A | Japan | A | |
| EP0807410B1 | European Patent Office (EPO) | B1 | |
| AT236578T | Austria | T | |
| ATE236578T1 | Austria | T1 | |
| DE69432488D1 | Germany | D1 | |
| EP0739606B1 | European Patent Office (EPO) | B1 | |
| AT244538T | Austria | T | |
| ATE244538T1 | Austria | T1 | |
| DE69628969D1 | Germany | D1 | |
| JP3462002B2 | Japan | B2 | |
| ES2196218T3 | Spain | T3 | |
| DE69432488T2 | Germany | T2 | |
| ES2201153T3 | Spain | T3 | |
| DE69628969T2 | Germany | T2 |
58 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Notification of lapseLapsedST | ST | FR | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Partial transmission of propertyTQ | TQ | FR | |
| Partial transmission of propertyTQ | TQ | FR | |
| Partial transmission of propertyTQ | TQ | FR | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation filedET | ET | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP3 | RAP3 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0807410
- Application
- 971122213
Titles3
- German
- Elektrolytische abtrennbare Verbindung bei endovaskulären Embolievorrichtungen
- English
- Electrolytically severable joint for endovascular embolic devices
- French
- Jointure séparable par voie électrolytique, pour dispositifs emboliques endovasculaires
Classification
- CPC, 5
- A61B17/12022
- A61B17/12113
- A61B17/12145
- A61B2017/00004
- A61B2017/12063
- IPC, 2
- A61B17 00
- A61B17 12
Designated states1
- Contracting states, 1
- Sweden